Peptides / Growth hormone axis

Conjugate · 191 amino acids · 23,305.1 Da

Somapacitan

ApprovedBanned in sport

Somapacitan (Sogroya) is an albumin-binding growth hormone analog approved in the US and EU for growth hormone deficiency in adults and children, and banned in sport. Studies in people tested it on IGF-1 levels, height growth and blood sugar, and tracked side effects. PepBank shows 289 results on somapacitan from 41 studies in people, and 31 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Sogroya, somapacitan-beco

First 40 of 191 amino acids1 changed amino acid

Evidence level: Large trials in people289 of 320 results come from studies in people, including randomized trials.

Results in people

289

90% of 320 results

Results in animals

7% of 320 results

Results in lab cells

3% of 320 results

From computer models

0% of 320 results

Overview

Somapacitan at a glance

What it is	Conjugate, 191 amino acids
Approval	Approved in the US and EU (Sogroya, 2020)
In sport	Banned in sport (WADA S2.2.3)
Studies	46 studies with results. All of them gave somapacitan, with 320 results. 289 in people23 in animals8 in lab cells
Best study in people	Randomized controlled trial with 200 people (2022)
Clinical trials	21 registered: 8 active or planned, 8 with posted results
Community use	Adults with GHD who are treatment naive or switching from daily somatropin. This starting regimen excludes patients aged 65 years and older, women receiving oral estrogen, and patients with moderate or severe hepatic impairment.

The science

What is somapacitan?

Somapacitan is a 191-residue growth hormone analog with an albumin-binding side chain at Cys101.

191

Amino acids in one chain

The history of somapacitan

2012January
A registered trial of somapacitan started (NCT01514500).
2017
The oldest paper on somapacitan in PepBank is from 2017.
2020August
FDA approved Sogroya for replacement of endogenous GH in adults with GHD. Treatment of pediatric patients aged 2.5 years and older with growth failure due to inadequate endogenous GH secretion, short stature born SGA without catch-up growth by age 2, growth failure associated with Noonan syndrome, or idiopathic short stature.

Somapacitan structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 191 amino acidsFrom the first amino acid to the last

F1PTIP5LS+RLF10−DNAML15+RAH+RL20HQLAF25−DTYQ−E30F−E−EAY35IP+K−EQ40+KYSFL45QNPQT50SLCFS55−ESIPT60PSN+R−E65−ETQQ+K70SNL−EL75L+RISL80LLIQS85WL−EPV90QFL+RS95VFANS100CVYGA105S−DSNV110Y−DLL+K115−DL−E−EG120IQTLM125G+RL−E−D130GSP+RT135GQIF+K140QTYS+K145F−DTNS150HN−D−DA155LL+KNY160GLLYC165F+R+K−DM170−D+KV−ET175FL+RIV180QC+RSV185−EGSCG190F

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Somapacitan is a conjugate of 191 amino acids, with a ring, 2 disulfide bonds, 1 changed amino acid.

Formula

C₁₀₃₈H₁₆₀₉N₂₇₃O₃₁₉S₉

Molecular weight

23,305.1 g/mol

CAS number

1338578-34-9

Target

Growth hormone receptor (gene GHR): agonistEvidence: Official prescribing information, mechanism of action

Development

Novo Nordisk. Highest phase: past the trial stage (see status).

Identifiers

ChEMBL CHEMBL3707290, UNII 8FOJ430U94, DrugBank DB15093

See charge, composition and 3D structure on the Scientific page

The evidence

What somapacitan studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people289 of 320 results come from studies in people, including randomized trials.

Growth hormone and growth

98 results · 94 in people · 4 animal

In children with GHD, growth speed was numerically lower with somapacitan than daily GH, within the trial's noninferiority limit. The Journal of clinical endocrinology and metabolism, 2022

Top results

In children with GHD, growth speed was numerically lower with somapacitan than daily GH, within the trial's noninferiority limit. (The Journal of clinical endocrinology and metabolism, 2022)
In girls with Turner syndrome, growth velocity was lower with somapacitan than daily GH, but met non-inferiority criteria. (The Journal of clinical endocrinology and metabolism, 2026)
In children with GHD, height scores were similar with somapacitan and daily GH. (Journal of the Endocrine Society, 2020)

Blood sugar

25 results · 25 in people

In GH-naïve adults, blood sugar changed less with somapacitan than daily GH at 34 weeks. Pituitary, 2023

Top results

In GH-naïve adults, blood sugar changed less with somapacitan than daily GH at 34 weeks. (Pituitary, 2023)
In children with GHD, somapacitan showed no clinically relevant changes in glucose metabolism. (Journal of the Endocrine Society, 2022)
In adults with GHD, HbA1c, fasting glucose, and insulin resistance did not differ significantly after switching from somatropin to somapacitan. (Journal of the Endocrine Society, 2026)

Weight and appetite

19 results · 17 in people · 2 animal

In adults with GH deficiency, somapacitan reduced trunk fat more than placebo. The Journal of clinical endocrinology and metabolism, 2020

Top results

In adults with GH deficiency, somapacitan reduced trunk fat more than placebo. (The Journal of clinical endocrinology and metabolism, 2020)
In Japanese adults with GH deficiency, visceral fat decreased from baseline with somapacitan and daily GH. (Frontiers in endocrinology, 2025)
In rats without a pituitary gland, somapacitan increased growth as the dose increased. (Growth hormone & IGF research, 2017)

Daily life and fitness

12 results · 12 in people

In Japanese adults with GHD, effectiveness scores numerically favored somapacitan over daily GH, without statistical significance. Journal of the Endocrine Society, 2020

Top results

In Japanese adults with GHD, effectiveness scores numerically favored somapacitan over daily GH, without statistical significance. (Journal of the Endocrine Society, 2020)
In adults with GH deficiency, switching to somapacitan was linked to improved handgrip strength. (The Journal of clinical endocrinology and metabolism, 2026)
In children with GHD, emotional scores numerically favored somapacitan over daily GH and exceeded the important-difference threshold, without statistical significance. (Journal of the Endocrine Society, 2020)

Immune system and inflammation

7 results · 7 in people

In adults receiving somapacitan, hs-CRP changes were positively linked to AST changes. Journal of endocrinological investigation, 2025

Top results

In adults receiving somapacitan, hs-CRP changes were positively linked to AST changes. (Journal of endocrinological investigation, 2025)
In children with GHD receiving somapacitan, no neutralizing antibodies against somapacitan were detected. (Journal of the Endocrine Society, 2022)
In adults with GHD, hs-CRP decreased from baseline after somapacitan therapy. (Journal of endocrinological investigation, 2025)

Liver

6 results · 6 in people

In adults with GHD, AST decreased slightly after somapacitan, but the change was not statistically significant. Journal of endocrinological investigation, 2025

Top results

In adults with GHD, AST decreased slightly after somapacitan, but the change was not statistically significant. (Journal of endocrinological investigation, 2025)
In adults with GHD, switching to somapacitan was linked to improved liver function after 6 months compared with baseline. (Medicine, 2023)
In adults with GH deficiency, AST improved after switching to somapacitan compared with the switch assessment. (Drug discoveries & therapeutics, 2026)

All 46 somapacitan studies by area Open the Scientific page

Key somapacitan studies

Studies in people come first, then studies in animals and in the lab.

People
Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
Miller et al. 2022 · The Journal of clinical endocrinology and metabolism · 200 people · cited by 65
10 results
People
RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial
2022 · Journal of the Endocrine Society · 200 people · cited by 0
11 results
People
Somapacitan Is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: A Randomized Controlled Phase 3 Study
Fu et al. 2026 · Hormone research in paediatrics · 110 people · cited by 9
7 results
People
Once-weekly somapacitan enhances linear growth in girls with Turner syndrome: a randomized controlled phase 3 study
Mauras et al. 2026 · The Journal of clinical endocrinology and metabolism · 105 people · cited by 0
5 results
People
Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial
Jorge et al. 2026 · European journal of endocrinology · 77 people · cited by 1
3 results

All 46 Somapacitan studies

Somapacitan clinical trials

ClinicalTrials.gov lists 21 trials of somapacitan. 8 are active or planned, and 8 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

Phase 3completed301 people

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

Phase 3completed200 people

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Phase 3completed110 people

All 14 Somapacitan trials

Status and safety

Is somapacitan approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.3.

Yes. Approved in the US and EU (Sogroya, 2020). The FDA label for Sogroya says: “Replacement of endogenous GH in adults with GHD” Banned in sport (WADA S2.2.3).

Laws and labels change, so check the regulator for the current status.

Somapacitan side effects and safety

PepBank has 83 safety results from studies of somapacitan. 83 of them come from studies in people.

Safety results from studies (83)

In Japanese adults with GH deficiency, adverse event rates were similar with somapacitan and daily GH. (Clinical endocrinology, 2020)
In Japanese adults with GHD, adverse event rates were similar with somapacitan and daily GH. (Journal of the Endocrine Society, 2020)
In children with GHD, injection-site reactions occurred in 5.3% with somapacitan and 5.9% with daily GH. (The Journal of clinical endocrinology and metabolism, 2022)
In children with GHD, injection-site reactions occurred in 5.3% with somapacitan and 5.9% with daily GH. (Journal of the Endocrine Society, 2022)
In girls with Turner syndrome, safety profiles were similar with somapacitan and daily GH. (The Journal of clinical endocrinology and metabolism, 2026)
In children with Noonan syndrome, somapacitan was well tolerated, with safety similar to daily GH. (European journal of endocrinology, 2026)
In children born SGA, safety and tolerability were reported as similar across the somapacitan and daily GH groups. (The Journal of clinical endocrinology and metabolism, 2025)
In Japanese adults with GH deficiency, somapacitan had a safety profile similar to daily GH. (Frontiers in endocrinology, 2025)
In children with GHD, adverse event types and frequencies showed no apparent pattern distinguishing somapacitan from daily GH. (Clinical endocrinology, 2017)
In adults with GH deficiency, adverse events were similar with somapacitan and daily GH. (The Journal of clinical endocrinology and metabolism, 2020)
In children born SGA, safety was similar with somapacitan and daily GH 0.035 mg/kg/day. (European journal of endocrinology, 2026)
In children with ISS, safety profiles were similar with somapacitan and daily GH. Most adverse events were mild. (European journal of endocrinology, 2026)
In children with GHD, fever was more frequent with the lowest initial somapacitan sequence than daily GH. (Journal of the Endocrine Society, 2020)
In children with GHD, somapacitan safety and tolerability were consistent with daily GH. (Journal of the Endocrine Society, 2020)
In adults without GHD, somapacitan trials in kidney and liver impairment found no new safety or tolerability issues. (Clinical pharmacokinetics, 2021)
In adults with GHD, nasopharyngitis, headache and fatigue were the most common adverse events with somapacitan and daily GH. (European journal of endocrinology, 2018)
In children continuing or switching to somapacitan, each other adverse event affected fewer than 10% of either group. (Journal of the Endocrine Society, 2022)
In healthy participants receiving somapacitan, no new safety issues were identified. (Clinical pharmacokinetics, 2024)
In children with prior injection pain, questionnaire responses favored somapacitan over somatrogon for pain at needle insertion. (Frontiers in endocrinology, 2026)
In healthy men given somapacitan, two subjects had six mild adverse events judged unlikely related to treatment. (European journal of pharmaceutical sciences, 2021)
In Japanese children with GHD receiving somapacitan, one mild injection-site reaction occurred. (Clinical endocrinology, 2024)
In adults with GH deficiency, no new diabetes cases occurred with somapacitan. (Pituitary, 2023)
In Chinese children with GHD, somapacitan was well tolerated, with a safety profile consistent with daily GH. (Hormone research in paediatrics, 2026)
In children with GHD, somapacitan was well tolerated, with a low proportion reporting injection-site reactions. (European journal of endocrinology, 2025)

See every safety result on the Scientific page

Doses studied (37 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.16 mg/kg/wk	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 200	Miller 2022
0.16 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 200	2022
0.16 mg/kg/week	Human	human	Not reported	52 weeks	Randomized trial in people · n = 110	Fu 2026
0.24 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 105	Mauras 2026
0.24 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 77	Jorge 2026
0.16 mg/kg/week	Human	human	Not reported	52 weeks	Randomized trial in people · n = 30	Mori 2024
.24 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people	Linglart 2026
0.16 mg/kg/week	Human	human	Not reported	Not reported	Randomized trial in people · n = 200	Miller 2025
0.16, 0.20, or 0.24 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 62	Juul 2025
0.02-0.16 mg/kg	Human	human	Not reported	Single dose	Randomized trial in people · n = 32	Battelino 2017
0.16 mg/kg/wk	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 28	Brod 2020
0.16/0.16 mg/kg/wk	Human	human	subcutaneous	156 weeks	Randomized trial in people	Sävendahl 2022
0.04, 0.08 or 0.16 mg/kg/wk during the first year, then 0.16 mg/kg/wk	Human	human	subcutaneous	156 weeks	Randomized trial in people	Sävendahl 2022
Somapacitan 0.04, 0.08 or 0.16 mg/kg/wk during the first year, then 0.16 mg/kg/wk; daily GH 0.034 mg/kg/d during the first year	Human	human	subcutaneous	156 weeks	Randomized trial in people	Sävendahl 2022
0.16 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people	Juul 2025
0.20 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people	Juul 2025
0.24 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people	Juul 2025
.24 mg/kg/week	Human	human	subcutaneous	52 weeks	Randomized trial in people	Abuzzahab 2026
0.04/0.16 mg/kg/wk	Human	human	subcutaneous	104 weeks	Randomized trial in people	Savendahl 2020
0.08/0.16 mg/kg/wk	Human	human	subcutaneous	104 weeks	Randomized trial in people	Savendahl 2020
0.08 mg/kg on days 1, 8, and 15	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 78	Bentz 2021
0.04, 0.08 or 0.16 mg/kg/week for 1 year, then 0.16 mg/kg/week for 3 years	Human	human	Not reported	4 years	Trial in people without random groups · n = 50	Sävendahl 2023
0.16 mg/kg/week	Human	human	Not reported	Not reported	Trial in people without random groups · n = 50	2022
mean 1.780 mg/week after titration (SD 1.058)	Human	human	Not reported	52 weeks	Trial in people without random groups · n = 46	Otsuka 2020
6 mg somapacitan containing tritium-labelled somapacitan 20 MBq	Human	human	subcutaneous	Single dose	Trial in people without random groups · n = 7	Helleberg 2021
0.02 mg/kg	Human	human	Not reported	Single dose	Trial in people without random groups · n = 6	Battelino 2017
0.16 mg/kg	Human	human	Not reported	Single dose	Trial in people without random groups · n = 6	Battelino 2017
0.16 mg/kg/week	Human	human	Not reported	1 year	Trial in people without random groups	Sävendahl 2023
0.16 mg/kg/week	Human	human	Not reported	Not reported	Trial in people without random groups	Sävendahl 2026
somapacitan 0.24 mg/kg/week after switch	Human	human	Not reported	week 52 to week 208	Trial in people without random groups	Juul 2026
0.24 mg/kg/week	Human	human	Not reported	week 52 to week 208	Trial in people without random groups	Juul 2026
0.16 mg/kg/week	Human	human	Not reported	52 weeks	Trial in people without random groups	Sävendahl 2026
0.16/0.16 mg/kg/wk	Human	human	subcutaneous	104 weeks	Trial in people without random groups	Savendahl 2020
0.16 mg/kg/wk	Human	human	subcutaneous	Not reported	Trial in people without random groups	Savendahl 2020
Starting at 0.16 mg/kg weekly, adjusted to IGF-1	Human	human	Not reported	Not reported	Observational study · n = 184	Al-Agha 2025
4 mg weekly	Human	human	Not reported	Not reported	Reports of single patients · n = 1	Rakusa 2024
90 mg	Animal	horse	subcutaneous	Not reported	Study in live animals · n = 3	Shimizu 2025

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label describes prescription Sogroya use. This record selects one adult starting regimen for the approved prefilled-pen solution.

Reported routines and cautions

What people use it for

Adults with GHD who are treatment naive or switching from daily somatropin. This starting regimen excludes patients aged 65 years and older, women receiving oral estrogen, and patients with moderate or severe hepatic impairment.S1

Reported regimens

Regimens that community sources report for Somapacitan. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Adults with GHD who are treatment naive or switching from daily somatropin. This starting regimen excludes patients aged 65 years and older, women receiving oral estrogen, and patients with moderate or severe hepatic impairment.Official label dosing of an approved product	subcutaneous injectionThe label specifies the upper arms, thigh, abdomen, or buttocks, with weekly rotation of the injection site.	1.5 mg per dose	once weekly	Not stated	Single official US label source.	S1

Cautions

The label contraindicates active malignancy. It also contraindicates acute critical illness after specified surgery or multiple accidental trauma, or with acute respiratory failure.S1

Status notes

Sogroya has EU authorisation for adults with GHD and children aged 3 years and above and adolescents with growth failure due to GHD.S2

Community sources

S1Sogroya US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This record covers one selected US adult label starting regimen. It does not establish a separate community regimen. The full label covers other populations, contraindications, interactions, monitoring, and pen instructions.

Questions and more

Ask a question about somapacitan

The answer links to every study it uses.

What does the evidence say about somapacitan?Is somapacitan tested in people?Compare with HGH (somatotropin)Compare with Lanreotide

Sources

Database: PepBank data for somapacitan (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about somapacitan

Somapacitan

ApprovedBanned in sport

Also known as Sogroya, somapacitan-beco

What it is

Conjugate, 191 amino acids

Approval

Approved in the US and EU (Sogroya, 2020)

In sport

Banned in sport (WADA S2.2.3)

Studies

46 studies with results. All of them gave somapacitan, with 320 results.
289 in people23 in animals8 in lab cells

Best study in people

Randomized controlled trial with 200 people (2022)

Clinical trials

21 registered: 8 active or planned, 8 with posted results

Community use

Adults with GHD who are treatment naive or switching from daily somatropin. This starting regimen excludes patients aged 65 years and older, women receiving oral estrogen, and patients with moderate or severe hepatic impairment.

Dose as reported

Class

Species

Route

Duration

Design

Source

0.16 mg/kg/wk

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 200

Miller 2022

0.16 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 200

2022

0.16 mg/kg/week

Human

human

Not reported

52 weeks

Randomized trial in people · n = 110

Fu 2026

0.24 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 105

Mauras 2026

0.24 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 77

Jorge 2026

0.16 mg/kg/week

Human

human

Not reported

52 weeks

Randomized trial in people · n = 30

Mori 2024

.24 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people

Linglart 2026

0.16 mg/kg/week

Human

human

Not reported

Randomized trial in people · n = 200

Miller 2025

0.16, 0.20, or 0.24 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 62

Juul 2025

0.02-0.16 mg/kg

Human

human

Not reported

Single dose

Randomized trial in people · n = 32

Battelino 2017

0.16 mg/kg/wk

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 28

Brod 2020

0.16/0.16 mg/kg/wk

Human

human

subcutaneous

156 weeks

Randomized trial in people

Sävendahl 2022

0.04, 0.08 or 0.16 mg/kg/wk during the first year, then 0.16 mg/kg/wk

Human

human

subcutaneous

156 weeks

Randomized trial in people

Sävendahl 2022

Somapacitan 0.04, 0.08 or 0.16 mg/kg/wk during the first year, then 0.16 mg/kg/wk; daily GH 0.034 mg/kg/d during the first year

Human

human

subcutaneous

156 weeks

Randomized trial in people

Sävendahl 2022

0.16 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people

Juul 2025

0.20 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people

Juul 2025

0.24 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people

Juul 2025

.24 mg/kg/week

Human

human

subcutaneous

52 weeks

Randomized trial in people

Abuzzahab 2026

0.04/0.16 mg/kg/wk

Human

human

subcutaneous

104 weeks

Randomized trial in people

Savendahl 2020

0.08/0.16 mg/kg/wk

Human

human

subcutaneous

104 weeks

Randomized trial in people

Savendahl 2020

0.08 mg/kg on days 1, 8, and 15

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 78

Bentz 2021

0.04, 0.08 or 0.16 mg/kg/week for 1 year, then 0.16 mg/kg/week for 3 years

Human

human

Not reported

4 years

Trial in people without random groups · n = 50

Sävendahl 2023

0.16 mg/kg/week

Human

human

Not reported

Trial in people without random groups · n = 50

2022

mean 1.780 mg/week after titration (SD 1.058)

Human

human

Not reported

52 weeks

Trial in people without random groups · n = 46

Otsuka 2020

6 mg somapacitan containing tritium-labelled somapacitan 20 MBq

Human

human

subcutaneous

Single dose

Trial in people without random groups · n = 7

Helleberg 2021

0.02 mg/kg

Human

human

Not reported

Single dose

Trial in people without random groups · n = 6

Battelino 2017

0.16 mg/kg

Human

human

Not reported

Single dose

Trial in people without random groups · n = 6

Battelino 2017

0.16 mg/kg/week

Human

human

Not reported

1 year

Trial in people without random groups

Sävendahl 2023

0.16 mg/kg/week

Human

human

Not reported

Trial in people without random groups

Sävendahl 2026

somapacitan 0.24 mg/kg/week after switch

Human

human

Not reported

week 52 to week 208

Trial in people without random groups

Juul 2026

0.24 mg/kg/week

Human

human

Not reported

week 52 to week 208

Trial in people without random groups

Juul 2026

0.16 mg/kg/week

Human

human

Not reported

52 weeks

Trial in people without random groups

Sävendahl 2026

0.16/0.16 mg/kg/wk

Human

human

subcutaneous

104 weeks

Trial in people without random groups

Savendahl 2020

0.16 mg/kg/wk

Human

human

subcutaneous

Not reported

Trial in people without random groups

Savendahl 2020

Starting at 0.16 mg/kg weekly, adjusted to IGF-1

Human

human

Not reported

Observational study · n = 184

Al-Agha 2025

4 mg weekly

Human

human

Not reported

Reports of single patients · n = 1

Rakusa 2024

90 mg

Animal

horse

subcutaneous

Not reported

Study in live animals · n = 3

Shimizu 2025

Context

Route

Amount

How often

How long

Agreement

Sources

subcutaneous injectionThe label specifies the upper arms, thigh, abdomen, or buttocks, with weekly rotation of the injection site.

1.5 mg per dose

once weekly

Not stated

Single official US label source.

Somapacitan

Somapacitan at a glance

What is somapacitan?

The history of somapacitan

Somapacitan structure and chemistry

What somapacitan studies show

Growth hormone and growth

Blood sugar

Weight and appetite

Daily life and fitness

Immune system and inflammation

Liver

Key somapacitan studies

Somapacitan clinical trials

Is somapacitan approved?

Somapacitan side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about somapacitan

Related peptides

Sources

Somapacitan

Somapacitan at a glance

What is somapacitan?

The history of somapacitan

Somapacitan structure and chemistry

What somapacitan studies show

Growth hormone and growth

Blood sugar

Weight and appetite

Daily life and fitness

Immune system and inflammation

Liver

Key somapacitan studies

Somapacitan clinical trials

Is somapacitan approved?

Somapacitan side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about somapacitan

Related peptides

Sources